Novel dysregulated long non‐coding RNAs in the acute kidney injury‐to‐chronic kidney diseases transition unraveled by transcriptomic analysis
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.70036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Bhupendra Puri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani, Rajasthan, India. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Acute Kidney Injury, Rats, Wistar, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Indian Council of Medical Research, Government of India, Indian Council of Medical Research.
Abstract (Originalsprache)
Acute kidney injury (AKI)‐to‐chronic kidney disease (CKD) transition involves a complex pathomechanism, including inflammation, apoptosis, and fibrosis where long non‐coding RNAs (lncRNAs) play a crucial role in their regulation. However, to date, only a few lncRNAs have been discovered to be involved in the AKI‐to‐CKD transition. Therefore, this study aims to investigate the dysregulated lncRNAs in the AKI‐to‐CKD transition in vitro and in vivo. To mimic AKI‐to‐CKD transition both in vivo and in vitro, bilateral ischemia‐reperfusion (IR) kidney injury was performed in Wistar rats (male), and normal rat kidney epithelial cell (NRK52E) cells were treated with exogenous transforming growth factor‐β1 (TGF‐β1). Further processing and analysis of samples collected from these studies (e.g., biochemical, histopathology, immunofluorescence, and RNA isolation) were also performed, and transcriptomic analysis was performed to identify the dysregulated lncRNAs. Rats subjected to IR showed a significant increase in kidney injury markers (creatinine, blood urea nitrogen (BUN), kidney injury molecule‐1(KIM‐1), and neutrophil gelatinase‐associated lipocalin (NGAL) along with altered cell morphology). Apoptosis, inflammation, and fibrosis markers were markedly increased during the AKI‐to‐CKD transition. Furthermore, transcriptomic analysis revealed 62 and 84 unregulated and 95 and 92 downregulated lncRNAs in vivo and in vitro, respectively. Additionally, functional enrichment analysis revealed their involvement in various pathways, including the tumor necrosis factor (TNF), wingless‐related integration site (Wnt), and hypoxia‐inducible factor‐1 (HIF‐1) signaling pathways. These identified dysregulated lncRNAs significantly contribute to AKI‐to‐CKD transition, and their knockin/out can aid in developing targeted therapeutic interventions against AKI‐to‐CKD transition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani, Rajasthan, India.
- Department of Biological Sciences, Birla Institute of Technology and Science Pilani, Pilani, Rajasthan, India.
ORCID-Profile: Anil Bhanudas Gaikwad
Förderung
- Indian Council of Medical Research, Government of India
- Indian Council of Medical Research
Zitieren
APA
Puri, B., Majumder, S., & Gaikwad, A. B. (2024). Novel dysregulated long non‐coding RNAs in the acute kidney injury‐to‐chronic kidney diseases transition unraveled by transcriptomic analysis. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70036
Vancouver
Puri B, Majumder S, Gaikwad AB. Novel dysregulated long non‐coding RNAs in the acute kidney injury‐to‐chronic kidney diseases transition unraveled by transcriptomic analysis. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70036
BibTeX
@article{Puri2024,
author = {Puri, Bhupendra and Majumder, Syamantak and Gaikwad, Anil Bhanudas},
title = {Novel dysregulated long non‐coding RNAs in the acute kidney injury‐to‐chronic kidney diseases transition unraveled by transcriptomic analysis},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.70036}
}
EUVIMED